Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer
Combining a BRAF inhibitor with a MEK inhibitor shrank tumours in about two thirds of previously treated patients with BRAF V600E-mutant lung cancer, far more than BRAF inhibition alone, leading to the first approval for this driver.
Overview
Phase 2 multicohort study; this cohort treated 57 patients with previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer with dabrafenib plus trametinib.
Objective response was 63.2 percent with a median progression-free survival of 9.7 months, compared with 33 percent for dabrafenib alone in an earlier cohort; pyrexia, nausea and fatigue were common.
- Objective response 63.2 percent.
- Median progression-free survival 9.7 months.
BRAF V600E is a routinely tested lung cancer driver, and BRAF plus MEK inhibition is the standard targeted therapy for it.
- Single-arm study with 57 patients.
- Non-V600 BRAF mutations do not respond.
Similar pages
not linked directly; found by shared links- Key paperDabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer
Shares BRAF V600E-mutant non-small-cell lung cancer, Dabrafenib, Trametinib, The Lancet Oncology.
- TrialStudy of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto
Shares Dabrafenib, Trametinib.
- Key paperDabrafenib plus trametinib in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma
Shares Dabrafenib, Trametinib.
- Key paperDabrafenib and trametinib in BRAF V600E-mutant anaplastic thyroid cancer (ROAR)
Shares Dabrafenib, Trametinib.
- Key paperCOMBI-d: dabrafenib and trametinib versus dabrafenib alone for BRAF V600-mutant melanoma
Shares Dabrafenib, Trametinib.
- Key paperCOMBI-AD: adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma
Shares Dabrafenib, Trametinib.
- Key paperDREAMseq (ECOG-ACRIN EA6134): sequencing dabrafenib-trametinib and nivolumab-ipilimumab in BRAF-mutant metastatic melanoma
Shares Dabrafenib, Trametinib.
- TrialCOMBI-AD
Shares Dabrafenib, Trametinib.